Abstract 215P
Background
Immunotherapy (IO) using programmed cell death protein 1 inhibitors is the standard of care in recurrent/metastatic head and neck cancer (R/M HNSCC). While response rate is almost 20% in the total population, a small percentage of patients shows exceptional response. Here, spatial whole transcriptome data were analysed to investigate potential compartment-specific associations of RNA expression with exceptional response to (IO).
Methods
Prospectively collected pre-treatment biopsies and clinicopathologic data of 50 IO-treated patients with R/M HNSCC were included in the study. Exceptional response (ER) was defined as complete or partial response (RECIST 1.1), lasting longer than 3 times the median response duration found in literature for the same treatment setting. Samples were evaluated using the GeoMx Human Whole Transcriptome Atlas (NanoString) assay for the in-situ quantification of 18,677 genes in the tumor (CK), leukocyte (CD45) and macrophage (CD68) tissue compartments. Differentially expressed genes (P<0.05, FDR 0.05) between ER and non-ER cases were identified in each compartment. Immune cell genes extracted from the “Single Cell RNA-Seq HNSCC” (CIBERSORTx) gene matrix and clinicopathologic characteristics; smoking, alcohol, sex, age, primary site and PD-L1 status, were investigated for correlations with ER.
Results
Seven exceptional responders were identified. Five immunoglobulin (Ig) genes (IGHG1, IGHG2, IGHG3, IGHG4, IGLL5) and one B-cell related gene (MZB1) showed the highest expression for exceptional responders both in the CD45 and CD68 compartments (stroma). Follicular dendritic cell secreted protein gene (FDCSP) was highly expressed in tumor. There was no association of ER with the immune-cell phenotypes derived from CIBERSORTx deconvolution. Alcohol consumption was the only clinicopathologic characteristic that showed association with ER (P=0.047).
Conclusions
ER to IO in R/M HNSCC is characterized by increased expression of Ig and B-cell related genes in tumor and stroma, indicating the importance of secreted immune factors for durable IO responses.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Rimm: Financial Interests, Personal, Advisory Board: AstraZeneca, Agendia, Cell Signaling Technology, Amgen, BMS, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, Konica/Minolta, GSK, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi, Ventana; Financial Interests, Institutional, Funding: Amgen, Cepheid, NavigateBP, NextCure, Konica/Minolta. A. Psyrri: Financial Interests, Personal, Invited Speaker: MSD, Merck Serono, EPICS; Financial Interests, Personal, Advisory Board: Pfizer, Sanofi, MSD, AstraZeneca, BMS, Leo, Rakuten, eTheRNA immunotherapies, Merck Serono, Seagen, Merus, Merus Pharmaceuticals, GSK; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Pfizer, GSK, Genesis, Incyte, Amgen, Debiopharm, MSD, Janssen, Lilly, Regeneron, Sanofi, BI, Roche, Peregrine, Oncolytics Biotech; Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Personal and Institutional, Steering Committee Member: Iovance, Pfizer, Roche; Financial Interests, Institutional, Steering Committee Member: Kura Oncology; Financial Interests, Personal, Steering Committee Member: Kura Oncology, GSK, Merus Pharmaceuticals; Financial Interests, Personal and Institutional, Funding: Kura Oncology, BMS, Roche, DEMO, Amgen, BI, Genesis, BMS, Pfizer, Oncolytics Biotech; Financial Interests, Institutional, Funding: Merck Serono, Pfizer, GSK; Financial Interests, Personal, Other, Educational activity: Medscape, Prime Oncology; Financial Interests, Institutional, Local PI: Novartis, Replimune. All other authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract